



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SECOND QUARTER					SIX MONTHS				
	2015	2014	% Change			2015	2014	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>CONSUMER SEGMENT <sup>(2)</sup></b>										
<b>BABY CARE</b>										
US	\$ 104	107	-2.8%	-2.8%	-	\$ 215	209	2.9%	2.9%	-
Intl	439	500	-12.2%	-1.0%	-11.2%	839	943	-11.0%	-0.9%	-10.1%
WW	543	607	-10.5%	-1.2%	-9.3%	1,054	1,152	-8.5%	-0.2%	-8.3%
<b>ORAL CARE</b>										
US	147	142	3.5%	3.5%	-	305	302	1.0%	1.0%	-
Intl	244	271	-10.0%	5.0%	-15.0%	489	522	-6.3%	6.9%	-13.2%
WW	391	413	-5.3%	4.5%	-9.8%	794	824	-3.6%	4.7%	-8.3%
<b>OTC</b>										
US	366	316	15.8%	15.8%	-	771	682	13.0%	13.0%	-
Intl	608	687	-11.5%	4.7%	-16.2%	1,196	1,332	-10.2%	6.8%	-17.0%
WW	974	1,003	-2.9%	8.2%	-11.1%	1,967	2,014	-2.3%	9.0%	-11.3%
<b>SKIN CARE</b>										
US	491	506	-3.0%	-3.0%	-	983	963	2.1%	2.1%	-
Intl	403	462	-12.8%	1.2%	-14.0%	814	919	-11.4%	1.4%	-12.8%
WW	894	968	-7.6%	-0.9%	-6.7%	1,797	1,882	-4.5%	1.8%	-6.3%
<b>WOMEN'S HEALTH</b>										
US	7	11	-36.4%	-36.4%	-	13	35	-62.9%	-62.9%	-
Intl	313	331	-5.4%	11.4%	-16.8%	594	634	-6.3%	8.6%	-14.9%
WW	320	342	-6.4%	9.9%	-16.3%	607	669	-9.3%	4.8%	-14.1%
<b>WOUND CARE / OTHER</b>										
US	240	238	0.8%	0.8%	-	427	438	-2.5%	-2.5%	-
Intl	121	173	-30.1%	-19.2%	-10.9%	227	322	-29.5%	-19.4%	-10.1%
WW	361	411	-12.2%	-7.6%	-4.6%	654	760	-13.9%	-9.6%	-4.3%
<b>TOTAL CONSUMER</b>										
US	1,355	1,320	2.7%	2.7%	-	2,714	2,629	3.2%	3.2%	-
Intl	2,128	2,424	-12.2%	2.1%	-14.3%	4,159	4,672	-11.0%	2.6%	-13.6%
WW	\$ 3,483	3,744	-7.0%	2.3%	-9.3%	\$ 6,873	7,301	-5.9%	2.8%	-8.7%

See footnotes at end of schedule

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	SECOND QUARTER					SIX MONTHS				
	2015	2014	% Change			2015	2014	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>PHARMACEUTICAL SEGMENT<sup>(2) (3)</sup></b>										
<b>IMMUNOLOGY</b>										
US	\$ 1,876	1,853	1.2%	1.2%	-	\$ 3,631	3,400	6.8%	6.8%	-
Intl	678	778	-12.9%	3.4%	-16.3%	1,386	1,574	-11.9%	3.4%	-15.3%
WW	2,554	2,631	-2.9%	1.9%	-4.8%	5,017	4,974	0.9%	5.7%	-4.8%
<b>REMICADE</b>										
US	1,088	1,021	6.6%	6.6%	-	2,143	2,018	6.2%	6.2%	-
US Exports <sup>(4)</sup>	241	357	-32.5%	-32.5%	-	422	524	-19.5%	-19.5%	-
Intl	339	426	-20.4%	-6.6%	-13.8%	703	872	-19.4%	-6.4%	-13.0%
WW	1,668	1,804	-7.5%	-4.2%	-3.3%	3,268	3,414	-4.3%	-1.0%	-3.3%
<b>SIMPONI / SIMPONI ARIA</b>										
US	172	132	30.3%	30.3%	-	327	236	38.6%	38.6%	-
Intl	136	150	-9.3%	9.2%	-18.5%	281	305	-7.9%	9.5%	-17.4%
WW	308	282	9.2%	19.1%	-9.9%	608	541	12.4%	22.2%	-9.8%
<b>STELARA</b>										
US	375	343	9.3%	9.3%	-	739	622	18.8%	18.8%	-
Intl	195	185	5.4%	26.5%	-21.1%	380	362	5.0%	24.6%	-19.6%
WW	570	528	8.0%	15.4%	-7.4%	1,119	984	13.7%	20.9%	-7.2%
<b>OTHER IMMUNOLOGY</b>										
US	-	-	-	-	-	-	-	-	-	-
Intl	8	17	-52.9%	-44.7%	-8.2%	22	35	-37.1%	-28.7%	-8.4%
WW	8	17	-52.9%	-44.7%	-8.2%	22	35	-37.1%	-28.7%	-8.4%
<b>INFECTIOUS DISEASES</b>										
US	381	1,020	-62.6%	-62.6%	-	793	1,581	-49.8%	-49.8%	-
Intl	651	742	-12.3%	7.2%	-19.5%	1,214	1,381	-12.1%	5.9%	-18.0%
WW	1,032	1,762	-41.4%	-33.2%	-8.2%	2,007	2,962	-32.2%	-23.8%	-8.4%
<b>EDURANT</b>										
US	9	6	50.0%	50.0%	-	18	11	63.6%	63.6%	-
Intl	92	86	7.0%	32.1%	-25.1%	174	162	7.4%	31.4%	-24.0%
WW	101	92	9.8%	33.2%	-23.4%	192	173	11.0%	33.4%	-22.4%
<b>OLYSIO / SOVRIAD</b>										
US	50	725	-93.1%	-93.1%	-	148	1,016	-85.4%	-85.4%	-
Intl	214	106	*	*	**	350	169	*	*	**
WW	264	831	-68.2%	-62.5%	-5.7%	498	1,185	-58.0%	-51.7%	-6.3%
<b>PREZISTA / PREZCOBIX</b>										
US	258	239	7.9%	7.9%	-	492	453	8.6%	8.6%	-
Intl	190	253	-24.9%	-7.7%	-17.2%	383	484	-20.9%	-4.8%	-16.1%
WW	448	492	-8.9%	-0.1%	-8.8%	875	937	-6.6%	1.7%	-8.3%
<b>OTHER INFECTIOUS DISEASES</b>										
US	64	50	28.0%	28.0%	-	135	101	33.7%	33.7%	-
Intl	155	297	-47.8%	-36.9%	-10.9%	307	566	-45.8%	-35.8%	-10.0%
WW	219	347	-36.9%	-27.5%	-9.4%	442	667	-33.7%	-25.2%	-8.5%

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	SECOND QUARTER					SIX MONTHS				
	2015	2014	% Change			2015	2014	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>NEUROSCIENCE</b>										
US	693	600	15.5%	15.5%	-	1,443	1,201	20.1%	20.1%	-
Intl	871	1,027	-15.2%	-0.2%	-15.0%	1,739	2,064	-15.7%	-1.7%	-14.0%
WW	1,564	1,627	-3.9%	5.6%	-9.5%	3,182	3,265	-2.5%	6.4%	-8.9%
<b>CONCERTA / METHYLPHENIDATE</b>										
US	102	28	*	*	-	228	63	*	*	-
Intl	104	117	-11.1%	2.7%	-13.8%	202	232	-12.9%	-0.3%	-12.6%
WW	206	145	42.1%	53.3%	-11.2%	430	295	45.8%	55.7%	-9.9%
<b>INVEGA</b>										
US	105	89	18.0%	18.0%	-	199	175	13.7%	13.7%	-
Intl	61	69	-11.6%	3.7%	-15.3%	122	148	-17.6%	-2.9%	-14.7%
WW	166	158	5.1%	11.8%	-6.7%	321	323	-0.6%	6.1%	-6.7%
<b>INVEGA SUSTENNA / XEPLION</b>										
US	253	202	25.2%	25.2%	-	481	384	25.3%	25.3%	-
Intl	183	192	-4.7%	14.6%	-19.3%	366	383	-4.4%	13.6%	-18.0%
WW	436	394	10.7%	20.1%	-9.4%	847	767	10.4%	19.4%	-9.0%
<b>RISPERDAL CONSTA</b>										
US	99	110	-10.0%	-10.0%	-	203	216	-6.0%	-6.0%	-
Intl	148	192	-22.9%	-6.5%	-16.4%	298	396	-24.7%	-9.8%	-14.9%
WW	247	302	-18.2%	-7.8%	-10.4%	501	612	-18.1%	-8.5%	-9.6%
<b>OTHER NEUROSCIENCE</b>										
US	134	171	-21.6%	-21.6%	-	332	363	-8.5%	-8.5%	-
Intl	375	457	-17.9%	-5.1%	-12.8%	751	905	-17.0%	-4.8%	-12.2%
WW	509	628	-18.9%	-9.6%	-9.3%	1,083	1,268	-14.6%	-5.9%	-8.7%
<b>ONCOLOGY</b>										
US	362	278	30.2%	30.2%	-	696	518	34.4%	34.4%	-
Intl	782	833	-6.1%	12.8%	-18.9%	1,556	1,615	-3.7%	14.1%	-17.8%
WW	1,144	1,111	3.0%	17.2%	-14.2%	2,252	2,133	5.6%	19.1%	-13.5%
<b>IMBRUVICA</b>										
US	89	33	*	*	-	155	39	*	*	-
Intl	65	9	*	*	**	115	13	*	*	**
WW	154	42	*	*	**	270	52	*	*	**
<b>VELCADE</b>										
US	-	-	-	-	-	-	-	-	-	-
Intl	344	403	-14.6%	1.1%	-15.7%	683	811	-15.8%	-1.5%	-14.3%
WW	344	403	-14.6%	1.1%	-15.7%	683	811	-15.8%	-1.5%	-14.3%
<b>ZYTIGA</b>										
US	255	235	8.5%	8.5%	-	508	464	9.5%	9.5%	-
Intl	291	327	-11.0%	8.6%	-19.6%	594	610	-2.6%	16.8%	-19.4%
WW	546	562	-2.8%	8.6%	-11.4%	1,102	1,074	2.6%	13.6%	-11.0%
<b>OTHER ONCOLOGY</b>										
US	18	10	80.0%	80.0%	-	33	15	*	*	-
Intl	82	94	-12.8%	5.3%	-18.1%	164	181	-9.4%	7.6%	-17.0%
WW	100	104	-3.8%	12.5%	-16.3%	197	196	0.5%	16.1%	-15.6%

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	<b>SECOND QUARTER</b>					<b>SIX MONTHS</b>				
	<b>2015</b>	<b>2014</b>	<b>% Change</b>			<b>2015</b>	<b>2014</b>	<b>% Change</b>		
			<b>Reported</b>	<b>Operational <sup>(1)</sup></b>	<b>Currency</b>			<b>Reported</b>	<b>Operational <sup>(1)</sup></b>	<b>Currency</b>
<b>CARDIOVASCULAR / METABOLISM / OTHER <sup>(5)</sup></b>										
US	1,231	862	42.8%	42.8%	-	2,351	1,653	42.2%	42.2%	-
Intl	421	516	-18.4%	-6.6%	-11.8%	863	1,020	-15.4%	-3.7%	-11.7%
WW	1,652	1,378	19.9%	24.3%	-4.4%	3,214	2,673	20.2%	24.6%	-4.4%
<b>XARELTO</b>										
US	472	361	30.7%	30.7%	-	913	680	34.3%	34.3%	-
Intl	-	-	-	-	-	-	-	-	-	-
WW	472	361	30.7%	30.7%	-	913	680	34.3%	34.3%	-
<b>INVOKANA / INVOKAMET</b>										
US	302	114	*	*	-	568	207	*	*	-
Intl	16	3	*	*	**	28	4	*	*	**
WW	318	117	*	*	**	596	211	*	*	**
<b>PROCRIT / EPREX</b>										
US	179	178	0.6%	0.6%	-	342	354	-3.4%	-3.4%	-
Intl	97	141	-31.2%	-18.7%	-12.5%	203	275	-26.2%	-13.3%	-12.9%
WW	276	319	-13.5%	-8.0%	-5.5%	545	629	-13.4%	-7.7%	-5.7%
<b>OTHER</b>										
US	278	209	33.0%	33.0%	-	528	412	28.2%	28.2%	-
Intl	308	372	-17.2%	-6.3%	-10.9%	632	741	-14.7%	-4.0%	-10.7%
WW	586	581	0.9%	7.9%	-7.0%	1,160	1,153	0.6%	7.5%	-6.9%
<b>TOTAL PHARMACEUTICAL</b>										
US	4,543	4,613	-1.5%	-1.5%	-	8,914	8,353	6.7%	6.7%	-
Intl	3,403	3,896	-12.7%	3.8%	-16.5%	6,758	7,654	-11.7%	3.8%	-15.5%
WW	\$ 7,946	\$ 8,509	-6.6%	1.0%	-7.6%	\$ 15,672	\$ 16,007	-2.1%	5.3%	-7.4%

See footnotes at end of schedule

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	SECOND QUARTER					SIX MONTHS				
	2015	2014	% Change			2015	2014	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>MEDICAL DEVICES <sup>(2)</sup></b>										
<b>CARDIOVASCULAR CARE</b>										
US	\$ 235	214	9.8%	9.8%	-	\$ 463	419	10.5%	10.5%	-
Intl	309	353	-12.5%	1.7%	-14.2%	610	689	-11.5%	2.5%	-14.0%
WW	544	567	-4.1%	4.7%	-8.8%	1,073	1,108	-3.2%	5.5%	-8.7%
<b>DIABETES CARE</b>										
US	214	222	-3.6%	-3.6%	-	426	414	2.9%	2.9%	-
Intl	280	336	-16.7%	-1.2%	-15.5%	552	656	-15.9%	-0.3%	-15.6%
WW	494	558	-11.5%	-2.1%	-9.4%	978	1,070	-8.6%	0.9%	-9.5%
<b>DIAGNOSTICS <sup>(6)</sup></b>										
US	-	232	**	**	-	-	456	**	**	-
Intl	16	229	-93.0%	-90.1%	-2.9%	46	448	-89.7%	-86.8%	-2.9%
WW	16	461	-96.5%	-95.0%	-1.5%	46	904	-94.9%	-93.5%	-1.4%
<b>ORTHOPAEDICS</b>										
US	1,321	1,294	2.1%	2.1%	-	2,630	2,586	1.7%	1.7%	-
Intl	1,009	1,175	-14.1%	-0.4%	-13.7%	2,028	2,304	-12.0%	1.2%	-13.2%
WW	2,330	2,469	-5.6%	0.9%	-6.5%	4,658	4,890	-4.7%	1.5%	-6.2%
<b>SPECIALTY SURGERY / OTHER</b>										
US	438	424	3.3%	3.3%	-	855	841	1.7%	1.7%	-
Intl	441	481	-8.3%	5.6%	-13.9%	857	938	-8.6%	4.6%	-13.2%
WW	879	905	-2.9%	4.5%	-7.4%	1,712	1,779	-3.8%	3.2%	-7.0%
<b>SURGICAL CARE</b>										
US	562	551	2.0%	2.0%	-	1,105	1,090	1.4%	1.4%	-
Intl	887	1,024	-13.4%	0.0%	-13.4%	1,767	1,993	-11.3%	1.5%	-12.8%
WW	1,449	1,575	-8.0%	0.7%	-8.7%	2,872	3,083	-6.8%	1.5%	-8.3%
<b>VISION CARE</b>										
US	243	262	-7.3%	-7.3%	-	496	548	-9.5%	-9.5%	-
Intl	403	445	-9.4%	6.0%	-15.4%	781	920	-15.1%	-1.0%	-14.1%
WW	646	707	-8.6%	1.1%	-9.7%	1,277	1,468	-13.0%	-4.1%	-8.9%
<b>TOTAL MEDICAL DEVICES</b>										
US	3,013	3,199	-5.8%	-5.8%	-	5,975	6,354	-6.0%	-6.0%	-
Intl	3,345	4,043	-17.3%	-3.9%	-13.4%	6,641	7,948	-16.4%	-3.5%	-12.9%
WW	\$ 6,358	7,242	-12.2%	-4.7%	-7.5%	\$ 12,616	14,302	-11.8%	-4.6%	-7.2%

\* Percentage greater than 100%

\*\* Not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Prior year amounts have been reclassified to conform to current year product disclosure

(4) Reported as U.S. sales

(5) Previously referred to as Other

(6) Reflects Diagnostics divestiture June 30, 2014